与事件时间数据的报告和解释有关的一些关键问题

Q2 Medicine

The Journal of rheumatology. Supplement Pub Date : 2022-05-15 DOI:10.3899/jrheum.220053

I. M. Schou

{"title":"与事件时间数据的报告和解释有关的一些关键问题","authors":"I. M. Schou","doi":"10.3899/jrheum.220053","DOIUrl":null,"url":null,"abstract":"Griffiths et al recently reported that in a cohort of Australian patients with ankylosing spondylitis included in the Optimising Patient outcomes in Australian RheumatoLogy (OPAL) dataset, the median persistence (persistence defined as the time to discontinuation of treatment) was longest for patients treated with golimumab (GOL) in all lines of therapy, and shortest for those treated with etanercept (ETN).1 In drawing this conclusion, the authors have overlooked some statistical aspects relating to the reporting of time-to-event data that make it difficult to evaluate the robustness of their conclusions.","PeriodicalId":35278,"journal":{"name":"The Journal of rheumatology. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Some Key Issues Relating to the Reporting and Interpretation of Time-to-Event Data\",\"authors\":\"I. M. Schou\",\"doi\":\"10.3899/jrheum.220053\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Griffiths et al recently reported that in a cohort of Australian patients with ankylosing spondylitis included in the Optimising Patient outcomes in Australian RheumatoLogy (OPAL) dataset, the median persistence (persistence defined as the time to discontinuation of treatment) was longest for patients treated with golimumab (GOL) in all lines of therapy, and shortest for those treated with etanercept (ETN).1 In drawing this conclusion, the authors have overlooked some statistical aspects relating to the reporting of time-to-event data that make it difficult to evaluate the robustness of their conclusions.\",\"PeriodicalId\":35278,\"journal\":{\"name\":\"The Journal of rheumatology. Supplement\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of rheumatology. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3899/jrheum.220053\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of rheumatology. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.220053","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

Griffiths等人最近报道，在澳大利亚风湿病学优化患者结果(OPAL)数据集中纳入的澳大利亚强直性脊柱炎患者队列中，接受戈利木单抗(GOL)治疗的患者在所有治疗线中的中位持续时间(持续时间定义为停止治疗的时间)最长，接受依那西普(ETN)治疗的患者最短在得出这一结论时，作者忽略了与报告事件时间数据有关的一些统计方面，这使得很难评估其结论的稳健性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Some Key Issues Relating to the Reporting and Interpretation of Time-to-Event Data

Griffiths et al recently reported that in a cohort of Australian patients with ankylosing spondylitis included in the Optimising Patient outcomes in Australian RheumatoLogy (OPAL) dataset, the median persistence (persistence defined as the time to discontinuation of treatment) was longest for patients treated with golimumab (GOL) in all lines of therapy, and shortest for those treated with etanercept (ETN).1 In drawing this conclusion, the authors have overlooked some statistical aspects relating to the reporting of time-to-event data that make it difficult to evaluate the robustness of their conclusions.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Journal of rheumatology. Supplement Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Duncan A. Gordon, The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 36 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.